Medinice S.A.

Warsaw Stock Exchange ICE.WA

Medinice S.A. EBIT for the year ending December 31, 2023: USD -1.27 M

Medinice S.A. EBIT is USD -1.27 M for the year ending December 31, 2023, a -14.42% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Medinice S.A. EBIT for the year ending December 31, 2022 was USD -1.11 M, a -59.34% change year over year.
Medinice S.A. EBIT for the year ending December 31, 2021 was USD -696.87 K, a 12.51% change year over year.
Medinice S.A. EBIT for the year ending December 31, 2020 was USD -796.50 K, a -35.90% change year over year.
Medinice S.A. EBIT for the year ending December 31, 2019 was USD -586.09 K, a -24.97% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Warsaw Stock Exchange: ICE.WA

Medinice S.A.

CEO	Mr. Sanjeev Choudhary
IPO Date	Sept. 1, 2018
Location	Poland
Headquarters	ul. Chmielna 132/134
Employees	16
Sector	Health Care
Industries Medical Instruments Biotechnology Pharmaceuticals

Description

Medinice S.A. provides medical solution for cardiology and cardiac surgery. The company support scientists for product commercialization including prototyping, clinical trials and certification, and product sales. Medinice S.A. was founded in 2012 and is based in Warsaw, Poland.

Key trends

Past 5 years